TRAIL and Its Receptors As Targets for Cancer Therapy

Overview

Journal Cancer Sci

Specialty Oncology

Date 2004 Oct 27

PMID 15504243

Citations 74

Authors

Hideo Yagita

Kazuyoshi Takeda

Yoshihiro Hayakawa

Mark J Smyth

Ko Okumura

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptotic cell death in a variety of tumor cells by engaging the death receptors DR4 and DR5, while sparing most normal cells. Preclinical studies in mice and non-human primates have shown the potential utility of recombinant soluble TRAIL and agonistic anti-DR5 or DR4 antibodies for cancer therapy. Moreover, we have recently revealed a vital role for endogenously expressed TRAIL in immunosurveillance of developing and metastatic tumors. In this review, we summarize recent knowledge about TRAIL and its receptors as promising targets for cancer therapy.

Citing Articles

Molecular signatures in prion disease: altered death receptor pathways in a mouse model.

Giri R J Transl Med. 2024; 22(1):503.

PMID: 38802941 PMC: 11129387. DOI: 10.1186/s12967-024-05121-x.

Effect of Zebularine on Apoptotic Pathways in Hepatocellular Carcinoma Cell Lines.

Sanaei M, Kavoosi F Int J Prev Med. 2023; 14:63.

PMID: 37351028 PMC: 10284256. DOI: 10.4103/ijpvm.ijpvm_191_21.

Antioxidant capacity and cytotoxic effect of an optimized extract of isabella grape () on breast cancer cells.

Velez M, Llano-Ramirez M, Ramon C, Rojas J, Bedoya C, Arango-Varela S Heliyon. 2023; 9(6):e16540.

PMID: 37260897 PMC: 10227348. DOI: 10.1016/j.heliyon.2023.e16540.

Plant-derived extracellular vesicles: Recent advancements and current challenges on their use for biomedical applications.

Lian M, Chng W, Liang J, Yeo H, Lee C, Belaid M J Extracell Vesicles. 2022; 11(12):e12283.

PMID: 36519808 PMC: 9753580. DOI: 10.1002/jev2.12283.

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems.

Zeinabad H, Szegezdi E Cancers (Basel). 2022; 14(20).

PMID: 36291908 PMC: 9600485. DOI: 10.3390/cancers14205125.

References

Kim S, Choi K, Kwon D, Benveniste E, Choi C . Ubiquitin-proteasome pathway as a primary defender against TRAIL-mediated cell death. Cell Mol Life Sci. 2004; 61(9):1075-81. PMC: 11138569. DOI: 10.1007/s00018-004-3477-5. View

Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K . Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol. 1999; 162(5):2639-47. View

Leverkus M, Sprick M, Wachter T, Mengling T, Baumann B, Serfling E . Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol. 2003; 23(3):777-90. PMC: 140698. DOI: 10.1128/MCB.23.3.777-790.2003. View

Kayagaki N, Yamaguchi N, Abe M, Hirose S, Toshikazu Shirai , Okumura K . Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell Immunol. 2003; 219(2):82-91. DOI: 10.1016/s0008-8749(02)00602-0. View

Seki N, Hayakawa Y, Brooks A, Wine J, Wiltrout R, Yagita H . Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003; 63(1):207-13. View

Fanger N, Maliszewski C, Schooley K, Griffith T . Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med. 1999; 190(8):1155-64. PMC: 2195665. DOI: 10.1084/jem.190.8.1155. View

Zhang X, Franco A, Nguyen T, Gray C, Hersey P . Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol. 2001; 164(8):3961-70. DOI: 10.4049/jimmunol.164.8.3961. View

Ursini-Siegel J, Zhang W, Altmeyer A, Hatada E, Do R, Yagita H . TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol. 2002; 169(10):5505-13. DOI: 10.4049/jimmunol.169.10.5505. View

Lamhamedi-Cherradi S, Zheng S, Maguschak K, Peschon J, Chen Y . Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol. 2003; 4(3):255-60. DOI: 10.1038/ni894. View

10.

Qin J, Chaturvedi V, Bonish B, Nickoloff B . Avoiding premature apoptosis of normal epidermal cells. Nat Med. 2001; 7(4):385-6. DOI: 10.1038/86401. View

11.

Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K . Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood. 1999; 93(8):2738-47. View

12.

Griffith T, Wiley S, Kubin M, Sedger L, Maliszewski C, Fanger N . Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999; 189(8):1343-54. PMC: 2193036. DOI: 10.1084/jem.189.8.1343. View

13.

Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30. DOI: 10.1038/nrc821. View

14.

Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T . Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res. 2004; 64(3):1037-43. DOI: 10.1158/0008-5472.can-03-1808. View

15.

Degli-Esposti M . To die or not to die--the quest of the TRAIL receptors. J Leukoc Biol. 1999; 65(5):535-42. DOI: 10.1002/jlb.65.5.535. View

16.

Spierings D, de Vries E, Vellenga E, van den Heuvel F, Koornstra J, Wesseling J . Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 2004; 52(6):821-31. DOI: 10.1369/jhc.3A6112.2004. View

17.

Shankar S, Singh T, Chen X, Thakkar H, Firnin J, Srivastava R . The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol. 2004; 24(5):1133-40. View

18.

Oshima K, Yanase N, Ibukiyama C, Yamashina A, Kayagaki N, Yagita H . Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells. Cytokine. 2001; 14(4):193-201. DOI: 10.1006/cyto.2001.0873. View

19.

Chen Q, Gong B, Zhou A, Hsi E, Hussein M, Almasan A . Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001; 98(7):2183-92. PMC: 1350927. DOI: 10.1182/blood.v98.7.2183. View

20.

Lunemann J, Waiczies S, Ehrlich S, Wendling U, Seeger B, Kamradt T . Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol. 2002; 168(10):4881-8. DOI: 10.4049/jimmunol.168.10.4881. View